ArticleMedical physics2025
Validation of the collapsed-cone superposition for whole-body patient-specific dosimetry in [177Lu]Lu-PSMA-617 radionuclide therapy.
Article in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical value of per-treatment whole-body single-time-point automated dosimetry for [European journal of nuclear medicine and molecular imaging · 2026Article
- Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study.EJNMMI research · 2026Article
- Validation of the collapsed-cone superposition for whole-body patient-specific dosimetry in [177Lu]Lu-PSMA-617 radionuclide therapy.Medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPatient-specific dosimetry in radiopharmaceutical therapy (RPT) offers a promising approach to optimize the balance between treatment efficacy and toxicity. The introduction of 360° CZT gamma cameras enables the development of personalized dosimetry studies using whole-body single photon emission computed tomography and computed tomography (SPECT/CT) data. PURPOSE: This study proposes to validate the collapsed-cone superposition (CCS) approach against Monte Carlo (MC) simulations for whole-body dosimetry of [177Lu]Lu-PSMA-617 therapy in patients with metastatic castration resistant prostate cancer (mCRPC). MATERIALS AND
methodsThirty patients with mCRPC were retrospectively included in this study. SPECT/CT images were acquired after the infusion of [177Lu]Lu-PSMA-617 therapy. SimpleDose was used to generate dose-rate maps (mGy/h) from a single SPECT/CT scan. The dosimetry relies on the CCS approach, which adjusts dose-point kernels according to tissue densities. Organ and lesion delineation were automated using the nnU-Net V2 neural network. MC simulations were performed with GATE 10 for 10
resultsAbsolute percentage errors (APE) between CCS and MC were < 5% for all organs and lesions. Compared to CCS,
conclusionCCS showed high agreement with MC with greater computational efficiency, demonstrating its clinical potential for whole-body dosimetry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.